> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Aeglea Bio BLA for Arginase 1 Deficiency
- URL: https://www.fdaweb.com/aeglea-bio-bla-for-arginase-1-deficiency/
- Published: 2022-04-13T12:00:00.000Z
- Updated: 2026-09-14T17:40:29.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5151589

Aeglea BioTherapeutics has submitted a BLA for pegzilarginase for treating Arginase 1 Deficiency (ARG1-D). The company says the recombinant human arginase 1 enzyme has been shown in clinical trials to normalize the elevated levels of the amino acid arginine in patients with ARG1-D. It says people living with ARG1-D experience severe spasticity-related mobility limitations, seizures, developmental delay, intellectual disability, and early mortality. In the studies, most treatment-emergent adverse events were mild or moderate in severity and there were no discontinuations due to treatment-emergent adverse events, Aeglea Bio says.